MapLight Therapeutics, Inc. (MPLT) Investor Relations Documents

MapLight Therapeutics, Inc. (MPLT) investor relations documents from the company's IR site: 9 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2025-10-06	Press release	MapLight Therapeutics Announces Commencement of Initial Public Offering
2025-09-17	Press release	MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M₁/M₄ Muscarinic Agonist ML-007C-MA for the Treatme
2025-07-28	Press release	MapLight Therapeutics Announces $372.5 Million Series D Financing
2025-07-07	Press release	MapLight Therapeutics Announces Initiation of Phase 2 Trial of Its Novel M₁/M₄ Muscarinic Agonist ML-007C-MA for the Tre
2024-12-02	Press release	MapLight Therapeutics Announces Results from Phase 1 Trial
2024-04-03	Press release	MapLight Therapeutics Appoints Maria Walker to Board of Directors
2024-03-28	Press release	MapLight Therapeutics Announces Initiation of Phase 1 Clinical Trial for ML-007/PAC, Under Development for Schizophrenia
2024-03-18	Press release	MapLight Therapeutics Expands Executive Leadership Team With Appointment of Vishwas Setia as Chief Financial Officer
2024-01-03	Press release	MapLight Therapeutics Announces Completion of Phase 1 Clinical Trial for Novel M₁/M₄ Muscarinic Agonist in Development f

MPLT overview · MPLT earnings · MPLT financials · MPLT KPIs · MPLT ownership · MPLT peers · MPLT filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.